AERI:NSD-Aerie Pharmace (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 15.25

Change

0.00 (0.00)%

Market Cap

USD 0.75B

Avg Analyst Target

USD 14.94 (-2.05%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AERI Stock Forecast & Price:
Based on the Aerie Pharmace stock forecasts from 6 analysts, the average analyst target price for Aerie Pharmace is USD 14.94 over the next 12 months. Aerie Pharmace’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Aerie Pharmace is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Aerie Pharmace’s stock price was USD 15.25. Aerie Pharmace’s stock price has changed by +0.00% over the past week, +0.20% over the past month and +59.35% over the last year.

About Aerie Pharmace (AERI:NSD)

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products includ ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-11-29 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
PPD PPD Inc

N/A

USD16.61B 47.04 21.58
VTRS Viatris Inc

+0.12 (+1.08%)

USD13.51B 16.88 7.03
NBIX Neurocrine Biosciences Inc

+0.08 (+0.07%)

USD11.74B 200.25 100.03
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
ITCI Intracellular Th

+0.69 (+1.32%)

USD4.95B N/A -14.08
LNTH Lantheus Holdings Inc

-0.24 (-0.39%)

USD4.02B 39.76 18.35
ALKS Alkermes Plc

+0.05 (+0.21%)

USD3.98B N/A -68.64
EVO Evotec SE ADR

-0.28 (-3.23%)

USD3.20B 444.00 -19.91

ETFs Containing AERI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 117.24% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 117.24% 99% A+ 99% A+
Trailing 12 Months  
Capital Gain 50.99% 94% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.99% 94% A 97% A+
Trailing 5 Years  
Capital Gain -76.26% 45% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -76.26% 45% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain -29.80% 21% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.80% 21% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 32.86% 72% C- 49% F
Risk Adjusted Return -90.70% 21% F 5% F
Market Capitalization 0.75B 80% B- 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 34.26 6% F 3% F
Price / Cash Flow Ratio -7.60 80% B- 68% D+
EV/EBITDA -350.17 99% A+ 98% A+
Management Effectiveness  
Return on Equity -2,255.01% 1% F 1% F
Return on Invested Capital -20.79% 55% F 35% F
Return on Assets -4.59% 66% D 42% F
Debt to Equity Ratio -1,353.07% 98% A+ 97% A+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.91 70% C- 59% F
Short Percent 3.13% 54% F 42% F
Beta -0.06 90% A- 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.